TY - JOUR T1 - Cancer Moonshot Immuno-Oncology Translational Network (IOTN): accelerating the clinical translation of basic discoveries for improving immunotherapy and immunoprevention of cancer JF - Journal for ImmunoTherapy of Cancer JO - J Immunother Cancer DO - 10.1136/jitc-2020-000796 VL - 8 IS - 1 SP - e000796 AU - Ananth Annapragada AU - Andrew Sikora AU - Catherine Bollard AU - Jose Conejo-Garcia AU - Conrad Russell Cruz AU - Shadmehr Demehri AU - Michael Demetriou AU - Levon Demirdjian AU - Lawrence Fong AU - Mary Horowitz AU - Alan Hutson AU - Kathryn Kadash-Edmondson AU - Donald Kufe AU - Steven Lipkin AU - Song Liu AU - Claire McCarthy AU - Martin Morgan AU - Zachary Morris AU - Yang Pan AU - Marcelo Pasquini AU - Stephen Schoenberger AU - Eliezer Van Allen AU - Eduardo Vilar AU - Yi Xing AU - Wenjuan Zha AU - the IOTN Consortium AU - Adekunle Odunsi Y1 - 2020/06/01 UR - http://jitc.bmj.com/content/8/1/e000796.abstract N2 - Despite regulatory approval of several immune-based treatments for cancer in the past decade, a number of barriers remain to be addressed in order to fully harness the therapeutic potential of the immune system and provide benefits for patients with cancer. As part of the Cancer Moonshot initiative, the Immuno-Oncology Translational Network (IOTN) was established to accelerate the translation of basic discoveries to improve immunotherapy outcomes across the spectrum of adult cancers and to develop immune-based approaches that prevent cancers before they occur. The IOTN currently consists of 32 academic institutions in the USA. By leveraging cutting-edge preclinical research in immunotherapy and immunoprevention, open data and resource sharing, and fostering highly collaborative team science across the immuno-oncology ecosystem, the IOTN is designed to accelerate the generation of novel mechanism-driven immune-based cancer prevention and therapies, and the development of safe and effective personalized immuno-oncology approaches. ER -